

Docket No.: 65617US(54086)  
(PATENT)

**IN THE UNITED STATES PATENT DESIGNATED OFFICE (DO/US)**  
**(National Phase of International Appln.: PCT/AU04/001624**  
**Publication No. WO 2005/049009A1)**

In re Patent Application of:  
Adam McCluskey, et al.

International Application No.: PCT/AU04/001624

Confirmation No.: N/A

International Filing Date: November 22, 2004

Filed: Concurrently Herewith

Art Unit: N/A

For: **METHODS AND AGENTS FOR INHIBITING**  
**DYNAVIN-DEPENDENT ENDOCYTOSIS**

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, Applicants invite the attention of the Patent and Trademark Office to the references listed on the attached PTO/SB/08. Applicants respectfully request that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new U.S. national phase patent application submitted herewith.

Those documents which are marked with a double asterisk (\*\*) next to the Cite No. in the attached form PTO/SB/08 are not supplied because they have previously been transmitted by the International Bureau, along with the International Search Report, to all the Designated Offices in the corresponding international patent

U.S. National Phase Application of  
PCT/AU04/001624  
IDS

Attorney Docket No. 65617US(54086)

application No. PCT/AU04/001624, filed November 22, 2004. Copies of the International Search Report and Written Opinion are enclosed.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

Applicants submit that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 04-1105, under Order No. 65617US(54086). A duplicate copy of this paper is enclosed.

Dated: May 19, 2006

Respectfully submitted,

(By:

Jonathan M. Sparks, Ph.D.  
Registration No.: 53,624

For

Peter C. Lauro, Esq.  
Registration No.: 32,360  
EDWARDS ANGELL PALMER & DODGE LLP  
P.O. Box 55874  
Boston, Massachusetts 02205  
(617) 439-4444  
Attorneys/Agents For Applicant

10/580098  
IAP9 Rec'd PCT/PTO 19 MAY 2006

PTO/SB/08a (10-03)

Approved for use through 07/01/2006. OMB 0651-003  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO

Complete if Known

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet 1 of 1

Application Number Not Yet Assigned

Filing Date Concurrently Herewith

First Named Inventor Adam McCluskey

Art Unit N/A

Examiner Name Not Yet Assigned Walter Webb

Attorney Docket Number 65617US(54086)

## U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
AA*	US-5,892,096-A		04-06-1999	BREWER SCIENCE INC.	

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code-Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>3</sup>
BA**	WO 1997/013749-A		04-17-1997	ALLIEDSIGNAL INC.		
BB**	WO 1995/019169-A		07-20-1995	SUGEN INC. et al.		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \* CITE NO.: Those application(s) which are marked with an single asterisk (\*) next to the Cite No. are not supplied under 37 CFR 1.96(e)(2)(ii) because that application was filed after June 30, 2003 or is available in the IWP. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
CA**	Yuan et al. <i>Bioorganic &amp; Medicinal Chemistry</i> , 10, 2002, p4169-4183, "OSAR Studies of HIV-1 Integrase Inhibition".		
CB**	Gazit et al. <i>Journal of Medicinal Chemistry</i> , 1996, 39, p4905-4911, "Dimeric Benzylidenemalononitrile Tyrophostins: Potent Inhibitors of EGF Receptor Tyrosine Kinase <i>in Vitro</i> ".		

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature 545697	/Walter Webb/	Date Considered	05/20/2008
------------------------------	---------------	-----------------	------------

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /W.W./